SynthesisFrontiers in endocrinology2026
Efficacy and safety of selective serotonin reuptake inhibitors for diabetes mellitus with depression: a systematic review and meta-analysis.
Synthesis in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To evaluate the efficacy and safety of selective serotonin reuptake inhibitors (SSRIs) in patients with diabetes mellitus and comorbid depression. Methods: This study was registered in PROSPERO (CRD420261305439). Eight electronic databases were searched up to February 11, 2026 for randomized controlled trials comparing SSRIs plus usual care versus control. Outcomes included depressive symptoms (HDRS, BDI), anxiety (HARS), glycaemic control (HbA1c, FPG, PPG), and BMI. Meta-analyses were performed using random-effects models; subgroup analysis by follow-up duration and sensitivity analysis were conducted. Results: Nine RCTs (770 participants) were included. Overall, SSRIs did not significantly improve HDRS (MD = 0.16, 95% CI -0.69 to 1.01, Conclusion: Preliminary evidence suggests that SSRIs may offer modest antidepressant benefits when used for ≥ 6 months in diabetic patients with depression, but they may be associated with a small increase in anxiety scores and do not appear to improve glycaemic control or BMI. However, the overall certainty of evidence is low to moderate. Monitoring of early anxiety symptoms is recommended, and further high-quality RCTs are needed. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/, identifier CRD420261305439.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.